Pioneering cardiOimmunology,

We leverage the potential of immunotherapy to create and provide groundbreaking treatments for cardiovascular diseases. 

Polygon is pioneering the emerging field of cardio-immunology by exploring the dynamic interplay between the immune system and cardiovascular well-being.

Our research has unveiled the pivotal role played by immune cells in the initiation and progression of cardiovascular conditions.

Inspired by the success of immunotherapies in oncology, our approach harnesses the disease-fighting capabilities of the immune system.

Discover our 1st program EMOTION: Exploration and MOdulation of CD8+ T cells in myocardial infarction.

We showed that CD8+ T cells have a pathogenic role in acute myocardial infarction (Santos et al, Nature Communications, 2021).

Our PoC shows that targeting CD8+T cells in acute MI is highly protective in-vitro and in-vivo.

We have developed PLG-101, the first human
anti-CD8 monoclonal antibody.

Discover CARDINAL: our innovative Cardioimmunology Platform

Drug development programs

Biomarkers / Bio-Imaging Programs

Let's unite